Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
While considering the molecular pathogenesis
2022-01-03

While considering the molecular pathogenesis of an MPNST, the Ras/Raf/MEK/ERK, mTOR/AKT, p53, and PTEN pathways associated with tumor growth have been described (McCubrey et al., 2012). The involvement of receptor tyrosine kinases such as EGFR and TAM receptor families, and its associated molecular
-
br Acknowledgments This study was financially
2022-01-03

Acknowledgments This study was financially supported by National Science Center Poland grant No DEC-2011/02/A/NZ4/00031 (KKK), Jagiellonian University Medical College (Poland) grants: K/ZDS/007130 (SM) and K/ZDS/007131 (SM), COST Action CA15135 (DŁ, HS, KKK) and DFG INST 208/664-1 FUGG (HS). Than
-
In the current study Olfml knockdown increased YAP
2022-01-03

In the current study, Olfml1 knockdown increased YAP but decreased the respective target genes of canonical Wnt signaling and Hedgehog signaling, Axin2 and Gli1. YAP suppresses canonical Wnt via binding to Dishevelled and/or β-catenin [[39], [40], [41], [42]]. Tariki et al. reported that adenovirus-
-
br Conflict of interest br Funding This
2022-01-03

Conflict of interest Funding This work was supported by the National Institutes of Health MSK Cancer Center Support Grant/Core Grant [P30 CA008748]. The funding source had no involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report;
-
Theoretically the majority of resistance mechanisms identifi
2022-01-03

Theoretically, the majority of resistance mechanisms identified so far could be targeted by compounds that are already available, such as inhibitors of ER, PIK3CA/mTOR or FGFR1. However, the potential therapeutic advantage of combining these agents with standard HER2-targeting treatments must be wei
7820 records 522/522 page Previous First page 上5页 521522